Efgartigimod for the Treatment of Guillain-Barré Syndrome
Efgartigimod for the Treatment of Guillain-Barré Syndrome
Not yet recruiting · NCT06885762 · Registry updated 2025-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efgartigimod for the Treatment of Guillain-Barré Syndrome | Chronic Disease, Disease Attributes, Guillain-Barre syndrome, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Not yet recruiting | Phase 2 / Phase 3 | 2025-03-20 | NCT06885762 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhongming Qiu | 11 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||